Summit Corporation plc
("Summit" or "the Company")

NOTICE OF ANNUAL GENERAL MEETING

Oxford, UK, 29 July 2009 - Summit Corporation plc (AIM: SUMM), a UK
drug discovery company, announces that its Annual Report and Accounts
for the year ended 31 January 2009 ('Annual Report') together with
the Notice of Annual General Meeting ('AGM') and Proposed Capital
Reorganisation have been posted to shareholders.  Copies of the
Annual Report will also be available on the Company's website,
www.summitplc.com.

The AGM will be held at the Company's registered office, 91 Milton
Park, Abingdon, Oxfordshire, OX14 4RY, on Thursday, 20 August 2009 at
10am.

                              - ENDS -
For more information, please contact:
Summit plc
Steven Lee, PhD
Richard Pye, PhD
Tel: +44 (0)1235 443951
Panmure Gordon
Andrew Burnett / Rakesh Sharma (Corporate Finance)
Ashton Clanfield (Corporate Broking)
Tel: +44 (0)207 459 3600

About Summit plc
Summit plc is a UK based drug discovery company with a major focus on
developing new therapeutics from its iminosugar drug discovery
platform.
Summit believes iminosugars are the key to gaining access to several
disease mechanisms where classical drugs have had little success, and
thus offer a major opportunity for the discovery and development of
new medicines.
Carbohydrates (sugars) play critical roles in maintaining correct
functioning of many normal processes in healthy individuals and
errors in carbohydrate recognition or modification can lead to
malfunction in cells resulting in disease.

Iminosugars have the potential to mimic carbohydrates or to interact
with processes which manipulate carbohydrates to modify activity or
to correct aberrant function.  Additionally, the structural features
of iminosugars allow them to have, have important effects when
interacting with many other unexploited therapeutic targets.
Commercially, Summit has a track record of signing programme
agreements and currently has an out-licensed product portfolio
comprising of four drug programmes with BioMarin, Orient Europharma,
Evolva and the Lilly TB Drug Discovery Initiative.  In the future
these programmes may generate success based milestone payments and
royalties for Summit.
In addition, Summit owns Dextra Laboratories, a business unit that
operates independently to Summit, which offers specialist
carbohydrate chemistry services to third parties on a fee-for-service
or collaborative basis.
The company listed on the alternative investment market (AIM) of the
London Stock Exchange in October 2004 - symbol: SUMM.  Further
information about the company is available at www.summitplc.com.

---END OF MESSAGE---




This announcement was originally distributed by Hugin. The issuer is 
solely responsible for the content of this announcement.